Athira Pharma (NASDAQ:LONA – Get Free Report) was upgraded by Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
A number of other research firms have also commented on LONA. Mizuho dropped their price objective on Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Athira Pharma in a research note on Friday, August 7th. Finally, Citizens Jmp decreased their target price on Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating for the company in a research note on Monday, August 17th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Athira Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $17.33.
Check Out Our Latest Report on Athira Pharma
Athira Pharma Price Performance
Athira Pharma stock opened at $5.20 on Friday. The firm has a market cap of $48.83 million, a price-to-earnings ratio of -1.24 and a beta of 2.11. Athira Pharma has a fifty-two week low of $2.21 and a fifty-two week high of $14.21. The firm has a fifty day moving average price of $6.60 and a two-hundred day moving average price of $8.06.
Athira Pharma (NASDAQ:LONA – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.20). As a group, sell-side analysts expect that Athira Pharma will post -2.67 earnings per share for the current year.
About Athira Pharma
Athira Pharma, Inc is a clinical-stage biotechnology company focused on developing regenerative medicines for neurodegenerative diseases and other conditions involving impaired neuronal function. The company’s research has centered on the hepatocyte growth factor (HGF) biological pathway, which is associated with neuronal health, repair and regeneration.
Athira’s lead investigational product was fosgonimeton, also known as ATH-1017, an injectable therapy designed to activate the HGF/MET pathway.
Further Reading
- Five stocks we like better than Athira Pharma
- These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
- Meta Claims Frontier-Class AI Status With New Muse Wonder Models
- Berkshire Just Backed This Little-Known Stock—Should You Chase It?
- Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
